Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
grade C 58.36 1.46% 0.84
RGNX closed up 1.46 percent on Monday, March 18, 2019, on 1.86 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RGNX trend table...

Date Alert Name Type % Chg
Mar 18 Shooting Star Candlestick Bearish 0.00%
Mar 18 Pocket Pivot Bullish Swing Setup 0.00%
Mar 18 Multiple of Ten Bearish Other 0.00%
Mar 15 180 Bullish Setup Bullish Swing Setup 1.46%
Mar 15 Pocket Pivot Bullish Swing Setup 1.46%
Mar 15 Inside Day Range Contraction 1.46%
Mar 15 Wide Bands Range Expansion 1.46%
Mar 14 Wide Bands Range Expansion 7.10%
Mar 13 Narrow Range Bar Range Contraction 0.99%
Mar 13 NR7 Range Contraction 0.99%

Older signals for RGNX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Medical Genetics Wet Age Related Macular Degeneration Applied Genetics Retinitis Pigmentosa Gene Delivery Adeno Associated Virus X Linked Retinitis Pigmentosa Homozygous Familial Hypercholesterolemia Iduronidase
Is RGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 85.1
52 Week Low 26.8
Average Volume 553,300
200-Day Moving Average 60.4466
50-Day Moving Average 48.2962
20-Day Moving Average 53.452
10-Day Moving Average 56.146
Average True Range 3.0588
ADX 33.25
+DI 33.6247
-DI 16.3336
Chandelier Exit (Long, 3 ATRs ) 51.1336
Chandelier Exit (Short, 3 ATRs ) 53.6364
Upper Bollinger Band 61.4372
Lower Bollinger Band 45.4668
Percent B (%b) 0.81
BandWidth 29.878021
MACD Line 2.7279
MACD Signal Line 2.5312
MACD Histogram 0.1967
Fundamentals Value
Market Cap 1.8 Billion
Num Shares 30.9 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -21.70
Price-to-Sales 99.62
Price-to-Book 4.15
PEG Ratio 1.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 62.47
Resistance 3 (R3) 62.65 61.45 61.79
Resistance 2 (R2) 61.45 60.41 61.37 61.56
Resistance 1 (R1) 59.91 59.76 60.68 59.73 61.33
Pivot Point 58.71 58.71 59.10 58.63 58.71
Support 1 (S1) 57.17 57.67 57.94 56.99 55.39
Support 2 (S2) 55.97 57.02 55.89 55.16
Support 3 (S3) 54.43 55.97 54.94
Support 4 (S4) 54.25